Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BMRA vs NPCE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NPCE Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)
NPCE Overall Winner
6-Pillar Tally: BMRA 1 – 4 NPCE (1 Tie)
Matrix Metrics: BMRA 3 – 7 NPCE
As of Nov 16, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin), whereas NPCE carries 41.0/100 (SELL) at $7.76 (138.9x Forward P/E, -11.3% operating margin).
- Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. NPCE 41.0/100 SELL), NPCE captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-11.3% vs. -125.2% operating margin) and revenue trajectory (-15.5% vs. -8.3% YoY).
- Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BMRA vs NPCE
BMRA
Biomerica Inc
$1.33
-2.32% 1D
Market Cap
$6.0M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
0.67β · 62% Vol
Unified Composite Score
44.5
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
NPCE
Head-to-Head Winner
Neuropace, Inc. Common Stock
$7.76
+2.71% 1D
Market Cap
$412.6M
TTM Revenue
$103M
Forward P/E
138.9x
Beta / 30D Vol
1.32β · 139% Vol
Unified Composite Score
41.0
SELL
Tech 25.0
Fund 44.0
Flow 68.0
Mom 40.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (BMRA 1 – 4 NPCE)
1. Valuation Multiples
NPCE
Forward P/E
N/M
138.9x
Trailing P/E
N/M
138.9x
PEG Ratio
N/M
N/M
EV / Revenue
1.1x
4.6x
2. Growth & Scale
NPCE
Revenue Growth (YoY)
-8.3%
-15.5%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$4.3M
$103M
Market Cap
$6.0M
$412.6M
3. Profitability & Quality
NPCE
Gross Margin
0.9%
78.9%
Operating Margin
-125.2%
-11.3%
Net Profit Margin
-115.5%
-18.4%
Return on Equity (ROE)
-113.8%
-106.5%
4. Balance Sheet & Cash Flow
NPCE
Cash Generation (TTM)
-$3.2M
-$12M
Cash Flow Margin
-73.5%
-11.3%
Net Cash / Leverage
$1.1M Net Cash
$57M Net Debt (5.88x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BMRA
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
123.2% (45th %ile)
Put/Call OI Skew
N/A
0.01x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BMRA (3) vs NPCE (7)| Institutional Metric | BMRA | NPCE | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.0M | $412.6M | NPCE | |
| Trailing P/E Ratio | N/M | 138.9x | NPCE | |
| Forward P/E Ratio | N/M | 138.9x | NPCE | |
| Revenue Growth (YoY) | -8.3% | -15.5% | BMRA | |
| Operating Margin (TTM) | -125.2% | -11.3% | NPCE | |
| Net Profit Margin | -115.5% | -18.4% | NPCE | |
| Return on Equity (ROE) | -113.8% | -106.5% | NPCE | |
| 52-Week Range Position | 4% ($1–$3) | 16% ($5–$20) | NPCE | |
| Beta / 30D Volatility | 0.67β · 62% Vol | 1.32β · 139% Vol | BMRA | |
| Unified Institutional Score | 44.5 / 100 (HOLD) | 41.0 / 100 (SELL) | BMRA | |
| Trailing 12M Revenue (USD) | $4.3M | $103M | Scale | |
| Gross Profit Margin (TTM) | 0.9% | 78.9% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.1x EV/Rev | N/M PEG · 4.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$3.2M ($1.1M Net Cash) | -$12M ($57M Net Debt (5.88x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BMRA +8.37 pp
3M Horizon
BMRA +29.37 pp
6M Horizon
BMRA +10.48 pp
1Y Horizon
NPCE +7.48 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BMRA Revenue | NPCE Revenue | BMRA Op. Margin | NPCE Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -46.4% | N/A | BMRA |
| FY2020 | $10M | $40M | -41.0% | -31.7% | NPCE |
| FY2021 | $10M | $50M | -104.2% | -52.5% | NPCE |
| FY2022 | $20M | $50M | -24.0% | -89.6% | BMRA |
| FY2023 | $10M | $70M | -135.3% | -41.5% | NPCE |
| FY2024 | $10M | $80M | -117.6% | -27.1% | NPCE |
| FY2025 | $10M | $100M | -96.7% | -16.3% | NPCE |
| FY2026 | $0M | N/A | -119.5% | N/A | BMRA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BMRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NPCE
BREAKDOWN
Current IV
123.2%
IV Percentile
45th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NPCE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BMRA Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
NPCE Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ BMRA vs NPCE Key Questions & Quantitative Answers
As of Nov 16, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin), whereas NPCE carries 41.0/100 (SELL) at $7.76 (138.9x Forward P/E, -11.3% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. NPCE 41.0/100 SELL), NPCE captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-11.3% vs. -125.2% operating margin) and revenue trajectory (-15.5% vs. -8.3% YoY). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NPCE leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with NPCE at -15.5% YoY revenue growth and +0.0% YoY earnings growth on $103M TTM revenue (78.9% gross margin, -11.3% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while NPCE shifted +150.0%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NPCE.
NPCE screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas NPCE trades at 138.9x Forward P/E, 138.9x Trailing P/E, N/M PEG, and 4.6x EV/Revenue (-11.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus NPCE (-106.5% ROE) capital efficiency.
In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, NPCE carries 123.2% implied volatility (45th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 139% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NPCE vs BMRA · Reverse Pair
NPCE vs TMCI
· Sector Peer
NPCE vs SGHT
· Sector Peer
NPCE vs BVS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking